To establish an up-to-dete experimental study system for modern systemic immunology
- VernacularTitle:构建现代系统免疫学新的实验研究体系
- Author:
Feng GUO
- Publication Type:Journal Article
- Keywords:
allergy and immunology;
red blood cell immunity;
complement
- From:
Medical Journal of Chinese People's Liberation Army
1983;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Siegel et al (1981) first put forward a new concept of the erythrocyte immune system. Guo Feng et al (1982) were the first ones to find red blood cell could adhering to complement coated yeast cells, red blood cell could adhering to complement coated cancer cells in 1986, blood cells (including Red blood cell, white blood cell) could adhering to complement Coated Cancer cells in 1999, and erythrocytes accounted for 99% in the formation cosettes when adherent to cancer cells. In 2001, The author and his colleagues (2001) found that activity of red cell in enhancing lymphocyte CR1 innate immune activity (or T lymphocyte or NK cell activity ) might be related to ECR1 genomic density polymorphism. In 2005the author postulated the main pathway of erythrocyte innate immune reaction, and the proposed algorithm consisted of: activation of complements by antigen (cancer cells or yeast cells et al) adherence of C3b adherence to red blood cell adheherence to white blood cells activation of blood immune reaction system. The author hypothesized that in blood immune reaction against antigen, there were 4 essential elements: antigen, plasma (complement), red blood cells, and white blood cells. Red blood cells and complement might play an important role in regulation of blood immune reaction. We attempted to establisha new experimental system of modern immunology. As cancer cell (or yeast cells) is a kind of antigenic cell, which can activate immunoreaction of the blood, a new experimental system of hematogenic immunoreaction algorithm could be built. Changes in various immunity indexes, including blood cell adherence rate, Il-8, IL-6, IL-12, CD35, CD44, CD55, CD59, CD4, CD8, CD2, CD25,CXCR4, Fy6, ete, indicate that cancer cells (S180) can activate immunoreaction, of the blood. A new experimental systerm enables us to study the immanent relationship between whole blood cells and plasma, red blood cell and white blood cells in immunoreaction, and it also provides us a useful method to study innate and adaptative immunity, hematogenic immunoreaction road map, and clinical immunotherapy. It is a new system for experimental study of modern systemic immunology.
